TLSI Profile
TriSalus Life Sciences, Inc. is a pioneering immunotherapy company dedicated to advancing treatments for liver and pancreatic tumors through innovative therapeutic approaches. The company specializes in developing and commercializing cutting-edge immunotherapies designed to enhance the efficacy of cancer treatment. TriSalus Life Sciences’ flagship products include the TriNav Infusion System and the Pancreatic Retrograde Venous Infusion System, which are tailored for targeted delivery of treatments to liver and pancreatic tumors, respectively.
The TriNav Infusion System facilitates precise hepatic arterial infusion, ensuring that high concentrations of therapeutic agents are delivered directly to liver tumors. This targeted approach aims to maximize therapeutic impact while minimizing systemic exposure. Similarly, the Pancreatic Retrograde Venous Infusion System is engineered to address the challenges associated with treating pancreatic tumors by enabling targeted drug delivery through the venous system.
In addition to its infusion systems, TriSalus Life Sciences is developing SD-101, an investigational immunotherapeutic that leverages pressure-enabled drug delivery technology. This advanced therapeutic is designed to treat a range of malignancies, including hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. SD-101 represents a significant innovation in the field of immunotherapy, with the potential to improve outcomes for patients with challenging cancers.
Founded and headquartered in Westminster, Colorado, TriSalus Life Sciences is at the forefront of transforming cancer treatment through its novel therapeutic solutions. The company’s focus on integrating advanced delivery technologies with immunotherapy underscores its commitment to addressing unmet medical needs and advancing the field of oncology. TriSalus Life Sciences continues to pursue rigorous research and development efforts to bring its innovative therapies to market and improve the lives of cancer patients globally.
|
